Congratulations to GeoVax Labs, Inc. on receiving the BARDA Project NextGen Award to conduct their Phase 2b clinical study evaluating the company's next-generation COVID-19 vaccine candidate, GEO-CM04S1.
Phase 2b double-blinded study to compare the efficacy, safety, and immunogenicity of GEO-CM04S1 with a U.S. Food and Drug Administration (FDA)-approved mRNA COVID-19 vaccine. https://buff.ly/3KOt9ek #vaccine #manufacturing #MVA #immunotherapies $GOVX
Earlier this month at the Jefferies Global Healthcare Conference, Precision BioSciences, Inc. CFO Alex Kelly sat down with Precision AQ EVP & Managing Director, Hannah Deresiewicz, to discuss the company’s proprietary ARCUS® in vivo gene editing platform and pipeline with the aim of delivering lasting cures for patients with a range of genetic diseases where no adequate treatments exist. Discover the key features and differentiating characteristics that may enable ARCUS nucleases to drive durable therapeutic outcomes in chronic hepatitis B (PBGENE-HBV), m3243 primary mitochondrial myopathy (PBGENE-PMM), Duchenne muscular dystrophy (PBGENE-DMD) and beyond in Precision AQ's "Access to the Best and Brightest" series! Statements contained in this video by Precision Biosciences regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. A full description of risks and uncertainties can be found in Precision Biosciences filings with the Securities and Exchange Commission.
Congratulations to client argenx who announced the FDA approval of a new treatment for adults with chronic inflammatory demyelinating polyneuropathy (CIDP)!
Today we announced the FDA approval of a new treatment for adults with chronic inflammatory demyelinating polyneuropathy (CIDP). This approval marks a key advancement in the understanding of rare, autoimmune diseases, and we are proud to deliver a new, innovative option for the #CIDP community. #TogetherWeDiscover Learn more: https://bit.ly/45D76Rl
CytomX Therapeutics CEO and Chairman Sean McCarthy sat down with Precision AQ EVP & Managing Director, Hannah Deresiewicz, at the Jefferies Global Healthcare Conference earlier this month to discuss the company’s differentiated Probody platform designed to localize the activity of potent anticancer biologics, including T-cell engagers, ADCs, and cytokines in the tumor microenvironment to increase the therapeutic index. Learn more about CytomX’s pioneering work in the field of masked therapeutics and the Phase 1a data for its CX-904 program, partnered with #Amgen, which demonstrated a favorable safety profile and meaningful tumor reductions in pancreatic cancer, a very difficult to treat tumor type, in Precision AQ's "Access to the Best and Brightest" series!
Join client Resolution Therapeutics for an insightful R&D webinar next Friday, June 28th at 12:30pm BST / 7:30am EDT!
Resolution Therapeutics is excited to host an R&D webinar with a live Q&A on Friday 28th June at 12.30 BST / 7.30 EDT! The management team will be joined by expert hepatologist, Arun Sanyal, M.D., and will provide an in-depth update on the extended MATCH Phase 2 clinical study as well as discuss Resolution’s innovative macrophage cell therapy platform following the teams’ presentations at this year’s #EASL2024 Annual Congress. Register now and submit your questions in advance of the R&D webinar using the following link: https://lnkd.in/ecTGYD-w See you there! #ESLD #Macrophage #CellTherapy
Congratulations to client Spur Therapeutics on their exciting rebrand announcement! This marks the beginning of a thrilling new chapter for an exceptional team. We looking forward to seeing all that you will do.
Exciting announcement: Freeline is now Spur Therapeutics! Our new name and branding reflects our dedication to advancing the practice of genetic medicine, moving toward a new generation of therapies that can change the course of disease progression—and change the course of people’s lives. Check out our new website to learn more: www.spurtherapeutics.com Read the press release: https://lnkd.in/gGZJpQrN
Congratulations to client Disc Medicine on the announcement of positive clinical data across their portfolio, including additional data for bitopertin in #EPP, updated data from their Phase 1b trial of DISC-0974 for MF #anemia, and initial SAD data from their Phase 1 trial of DISC-3405!
Disc is thrilled to share positive clinical data across our portfolio at #EHA2024, including additional data for bitopertin in #EPP, updated data from our Phase 1b trial of DISC-0974 for MF #anemia, and initial SAD data from our Phase 1 trial of DISC-3405. Join us for our corporate call on Friday, June 14 at 8 am ET. Read more and register here: https://lnkd.in/eQshnEVw
With late-stage data in Alzheimer’s disease due in the coming months, Athira Pharma’s CEO, Mark Litton,Ph.D., sat down with Hannah Deresiewicz, EVP of Precision AQ, while at the Jefferies Global Healthcare Conference to discuss his excitement for the future and the Company’s novel approach to battling a variety of neurodegenerative diseases.
Jo Viney, Ph.D., Founder, President & CEO of Seismic Therapeutic, spoke with Precision AQ EVP & Managing Director, Hannah Deresiewicz, at the Jefferies Global Healthcare Conference last week to discuss Seismic's promising I&I pipeline and powerful IMPACT platform enabled by machine learning. Learn more about how Seismic is making a major shift in the discovery and development of immunology therapies in Precision AQ's "Access to the Best and Brightest" series!
